Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach

Chemical Biology and Drug Design

Volumn 86, Issue 2, 2015, Pages 180-189

  Zaytsev, Andrey ^a   Dodd, Barry ^a   Magnani, Matteo ^b   Ghiron, Chiara ^b   Golding, Bernard T ^a   Griffin, Roger J ^a   Liu, Junfeng ^c   Lu, Xiaohong ^c   Micco, Iolanda ^b   Newell, David R ^c   Padova, Alessandro ^b   Robertson, Graeme ^b   Lunec, John ^c   Hardcastle, Ian R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Siena Biotech SpA   (Italy)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

drug design; drug discovery; protein protein interaction; structure based drug design; virtual screening

Indexed keywords

BENZIMIDAZOLE; OXINDOLE; PROTEIN INHIBITOR; PROTEIN P53; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; MOLECULAR LIBRARY; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BINDING; PROTEIN MDM2; TP53 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; X RAY ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; PHARMACOLOGY; PRECLINICAL STUDY;

BENZIMIDAZOLES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NUCLEAR PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84947125800     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12474     Document Type: Article

References (51)

1. Toogood P.L., (2002) Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem; 45: 1543-1558.
2. Yin H., Hamilton A.D., (2005) Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem-Int Edit; 44: 4130-4163.
3. Wells J.A., McClendon C.L., (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature; 450: 1001-1009.
4. Azzarito V., Long K., Murphy N.S., Wilson A.J., (2013) Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem; 5: 161-173.
5. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B., (1992) Amplification of a gene encoding a P53-associated protein in human sarcomas. Nature; 358: 80-83.
6. Shvarts A., Steegenga W.T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R.C., et al,. (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J; 15: 5349-5369.
7. Toledo F., Wahl G.M., (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer; 6: 909-923.
8. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., Zwolinska A., et al,. (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med; 18: 1239-1247.
9. Momand J., Zambetti G.P., Olson D.C., George D., Levine A., (1992) The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell; 69: 1237-1245.
10. Fuchs S.Y., Adler V., Buschmann T., Wu X.W., Ronai Z., (1998) Mdm2 association with p53 targets its ubiquitination. Oncogene; 17: 2543-2547.
11. Haupt Y., Maya R., Kazaz A., Oren M., (1997) Mdm2 promotes the rapid degradation of p53. Nature; 387: 296-299.
12. Kubbutat M.H.G., Jones S.N., Vousden K.H., (1997) Regulation of p53 stability by Mdm2. Nature; 387: 299-303.
13. Marine J.-C.W., Dyer M.A., Jochemsen A.G., (2007) MDMX: from bench to bedside. J Cell Sci; 120: 371-378.
14. Francoz S., Froment P., Bogaerts S., De Clercq S., Maetens M., Doumont G., Bellefroid E., Marine J.C., (2006) Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA; 103: 3232-3237.
15. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P., (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science; 274: 948-953.
16. Weber L., (2010) Patented inhibitors of p53-Mdm2 interaction (2006-2008). Exp Opin Ther Patents; 20: 179-191.
17. Khoury K., Popowicz G.M., Holak T.A., Domling A., (2011) The p53-MDM2/MDMX axis-A chemotype perspective. MedChemComm; 2: 246-260.
18. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A., (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science; 303: 844-848.
19. Shangary S., Qin D., McEachern D., Liu M., Miller R.S., Qiu S., Nikolovska-Coleska Z., et al,. (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA; 105: 3933-3938.
20. Yu S., Qin D., Shangary S., Chen J., Wang G., Ding K., McEachern D., Qiu S., Nikolovska-Coleska Z., Miller R., Kang S., Yang D., Wang S., (2009) Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem; 52: 7970-7973.
21. Popowicz G.M., Dömling A., Holak T.A., (2011) The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed; 50: 2680-2688.
22. Mohammad R.M., Wu J., Azmi A.S., Aboukameel A., Sosin A., Wu S., Yang D., Wang S., Al-Katib A.M., (2009) An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer; 8: 230.
23. Vu B., Wovkulich P., Pizzolato G., Lovey A., Ding Q., Jiang N., Liu J.J., Zhao C., Glenn K., Wen Y., Tovar C., Packman K., Vassilev L., Graves B., (2013) Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med Chem Lett; 4: 466-469.
24. Ray-Coquard I., Blay J.-Y., Italiano A., Le Cesne A., Penel N., Zhi J., Heil F., Rueger R., Graves B., Ding M., Geho D., Middleton S.A., Vassilev L.T., Nichols G.L., Bui B.N., (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol; 13: 1133-1140.
25. Ding Q., Zhang Z., Liu J.-J., Jiang N., Zhang J., Ross T.M., Chu X.J., et al,. (2013) Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem; 56: 5979-5983.
26. Zhao Y., Liu L., Sun W., Lu J., McEachern D., Li X., Yu S., Bernard D., Ochsenbein P., Ferey V., Carry J.C., Deschamps J.R., Sun D., Wang S., (2013) Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc; 135: 7223-7234.
27. Popowicz G.M., Czarna A., Rothweiler U., Szwagierczak A., Krajewski M., Weber L., Holak T.A., et al,. (2007) Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle; 6: 2386-2392.
28. Popowicz G., Czarna A., Holak T., (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle; 7: 2441-2443.
29. Popowicz G.M., Czarna A., Wolf S., Wang K., Wang W., Dömling A., Holak T.A., (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle; 9: 1104-1111.
30. Macchiarulo A., Giacchè N., Carotti A., Baroni M., Cruciani G., Pellicciari R., (2008) Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. J Chem Inf Model; 48: 1999-2009.
31. Kallen J., Goepfert A., Blechschmidt A., Izaac A., Geiser M., Tavares G., Ramage P., Furet P., Masuya K., Lisztwan J., (2009) Crystal structures of human MdmX (HdmX) in complex with p53 peptide analogues reveal surprising conformational changes. J Biol Chem; 284: 8812-8821.
32. Joseph T.L., Madhumalar A., Brown C.J., Lane D.P., Verma C.S., (2010) Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle; 9: 1167-1181.
33. Reed D., Shen Y., Shelat A.A., Arnold L.A., Ferreira A.M., Zhu F., Mills N., Smithson D.C., Regni C.A., Bashford D., Cicero S.A., Schulman B.A., Jochemsen A.G., Guy R.K., Dyer M.A., (2010) Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem; 285: 10786-10796.
34. Graves B., Thompson T., Xia M., Janson C., Lukacs C., Deo D., Di Lello P., Fry D., Garvie C., Huang K.S., Gao L., Tovar C., Lovey A., Wanner J., Vassilev L.T., (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA; 109: 11788-11793.
35. Schneider G., Neidhart W., Giller T., Schmid G., (1999) "Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed; 38: 2894-2896.
36. Cramer R.D., Jilek R.J., Guessregen S., Clark S.J., Wendt B., Clark R.D., (2004) "Lead Hopping". Validation of topomer similarity as a superior predictor of similar biological activities. J Med Chem; 47: 6777-6791.
37. Luk K.-C., So S.-S., Zhang J., Zhang Z., (2006) Oxindole derivatives.
38. Zhang Z., Ding Q., Liu J.-J., Zhang J., Jiang N., Chu X.-J., Bartkovitz D., et al,. (2014) Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorg Med Chem; 22: 4001-4009.
39. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., et al,. (1988) Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem; 31: 2235-2246.
40. Hardcastle I.R., Ahmed S.U., Atkins H., Farnie G., Golding B.T., Griffin R.J., Guyenne S., et al,. (2006) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem; 49: 6209-6221.
41. Blackburn T.J., Ahmed S., Coxon C.R., Liu J.F., Lu X.H., Golding B.T., Griffin R.J, et al,. (2013) Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions. Medchemcomm; 4: 1297-1304.
42. CDCC (2005) GOLD. GOLD.
43. Bendale P.M., Sun C.-M., (2002) Rapid microwave-assisted liquid-phase combinatorial synthesis of 2-(Arylamino)benzimidazoles. J Comb Chem; 4: 359-361.
44. Chen L.-H., Chang C.-M., Salunke D.B., Sun C.-M., (2011) Divergent synthesis of unsymmetrical annulated biheterocyclic compound libraries: benzimidazole linked indolo-benzodiazepines/quinoxaline. ACS Comb Sci; 13: 391-398.
45. He Y., Wu B., Yang J., Robinson D., Risen L., Ranken R., Blyn L., Sheng S., Swayze E.E., (2003) 2-Piperidin-4-yl-benzimidazoles with broad spectrum antibacterial activities. Bioorg Med Chem Lett; 13: 3253-3256.
46. Vourloumis D., Takahashi M., Simonsen K.B., Ayida B.K., Barluenga S., Winters G.C., Hermann T., (2003) Solid-phase synthesis of benzimidazole libraries biased for RNA targets. Tetrahedron Lett; 44: 2807-2811.
47. Zou B., Yuan Q., Ma D., (2007) Synthesis of 1,2-disubstituted benzimidazoles by a Cu-catalyzed cascade aryl amination/condensation process. Angew Chem Int Ed; 46: 2598-2601.
48. Micco I., Nencini A., Quinn J., Bothmann H., Ghiron C., Padova A., Papini S., (2008) Parallel synthesis of a series of potentially brain penetrant aminoalkyl benzoimidazoles. Bioorg Med Chem; 16: 2313-2328.
49. Yang D., Fokas D., Li J., Yu L., Baldino C.M., (2005) A versatile method for the synthesis of benzimidazoles from o-nitroanilines and aldehydes in one step via a reductive cyclization. Synthesis; 2005: 47-56.
50. Egbertson M.S., Cook J.J., Bednar B., Prugh J.D., Bednar R.A., Gaul S.L., Gould R.J., et al,. (1999) Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene α-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J Med Chem; 42: 2409-2421.
51. Fry D.C., Wartchow C., Graves B., Janson C., Lukacs C., Kammlott U., Belunis C., Palme S., Klein C., Vu B., (2013) Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. ACS Med Chem Lett; 4: 660-665.